Navigation Links
Triple Analysis: Prostate Cancer, Angiogenesis and Peptides
Date:11/16/2011

NEW YORK, Nov. 16, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Triple Analysis: Prostate Cancer, Angiogenesis and Peptides

http://www.reportlinker.com/p0284661/Triple-Analysis-Prostate-Cancer-Angiogenesis-and-Peptides.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Prostate Cancer), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Peptides). Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Prostate Cancer

The prostate cancer report part comprises defined and up to date development strategies for 346 prostate cancer drugs within the portfolio of 198 investigators, from Ceased to Marketed. This report part extensively analyses 202 identified targets of prostate cancer drugs, organized into 187 drug target strategies, and assesses them in prostate cancer.

This part is based on the following publication:

A Decision Support Tool for Optimizing the Prostate Cancer Pipeline: From Research and Development to Market

Part II: Angiogenesis

The angiogenesis report part comprises defined and up to date development strategies for 239 drugs affecting angiogenesis in oncology within the portfolio of 148 investigators, from Preclinical to Marketed. This report part extensively analyses 174 identified targets of angiogenesis affecting drugs, organized into 167 drug target strategies, and assesses them in 64 different cancer indications.

This part is based on the following publication:

Commercializing Cancer Drugs Affecting Angiogenesis: A Decision Support Tool for Optimizing the Pipeline

Part III: Peptides

The cancer peptide drug report part comprises defined and up to date development strategies for 152 peptide drugs in oncology within the portfolio of 104 companies world-wide, from Ceased to Marketed. The report extensively analyses their 123 identified drug targets, organized into 103 drug target strategies, and assesses them in 56 cancer indications.

This part is based on the following publication:

Commercializing Peptides in Cancer: The Faster Route to Consider Your Options and Position of Others

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Prostate Cancer

5.1 The Scope of this Report 28

6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (202 Drug Targets) 32-383

7 Emerging New Products to Established Ones: Drug Target Strategies by their Highest Stage of Development in the Prostate Cancer Pipeline (187 Drug Target Strategies and 346 Drugs) 384-438

8 Compound Strategies at Work: Competitive Benchmarking of Prostate Cancer Drugs by Compound Strategy (8 Different Compound Strategies) 439-485

9 Pipeline and Portfolio Planning: Competitive Benchmarking of Prostate Cancer Therapeutic Pipeline by Investigator (198 Investigators) 486-820

11 Drug Index 822

12 Company Index 831

Figures: Includes 6 Figures

Tables: Includes 257 Tables

Total Number of Pages: 838

Part II: Angiogenesis

5.1 The Scope of this Report 35

6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (174 Drug Targets) 39-366

7 Emerging New Products to Established Ones: Drug Target Strategies of Cancer Drugs Affecting Angiogenesis by their Highest Stage of Development (167 Drug Target Strategies and 239 Drugs) 367-437

8 Compound Strategies at Work: Competitive Benchmarking of Cancer Drugs Affecting Angiogenesis by Compound Strategy (7 Different Compound Strategies) 438-485

9 Selecting Cancer Indications for Angiogenesis Affecting Drugs in Oncology (64 Cancer Indications) 486-643

10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (148 Investigators) 644-1211

10 Disclaimer 1212

11 Drug Index 1213

12 Company Index 1221

Figures: Includes 7 Figures

Tables: Includes 300 Tables

Total Number of Pages: 1227

Part III: Peptides

5.1 The Scope of this Report 26

6 Consider the Therapeutic Target Among Peptide Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (123 Drug Targets) 30-248

7 Emerging New Products to Established Ones: Drug Target Strategies of Peptide Drugs in Oncology by their Highest Stage of Development (103 Drug Targets Strategies and 152 Peptide Drugs) 249-372

8 Selecting Indication for Peptide Drugs in Oncology (56 Cancer Indications) 373-441

9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Peptide Drug Pipeline in Oncology by Investigator (104 Investigators and 152 Peptide Drugs) 442-895

10 Disclaimer 896

11 Drug Index 897

12 Company Index 902

Figures: Includes 5 Figures

Tables: Includes 207 Tables

Total Number of Pages: 906

To order this report:

: Triple Analysis: Prostate Cancer, Angiogenesis and Peptides

More  Market Research Report

Check our  Industry Analysis and Insights

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Triple Analysis: Apoptosis, Cancer Vaccines and Antibodies
2. Carrot Medical Positioned for Third Straight Year of Triple Digit Growth
3. Reportlinker Adds Triple Analysis: Colorectal Cancer, Lymphoma and Peptides
4. Reportlinker Adds Triple Analysis: Lymphoma, Pancreatic Cancer and Prostate Cancer
5. Reportlinker Adds Triple Analysis: Lymphoma, Prostate Cancer and Antibodies
6. Reportlinker Adds Triple Analysis: Colorectal Cancer, Lymphoma and Pancreatic Cancer
7. Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis
8. Reportlinker Adds Triple Analysis: Lymphoma, Melanoma and Peptides
9. Reportlinker Adds Triple Analysis: Leukemia, Lymphoma and Peptides
10. Reportlinker Adds Triple Analysis: Breast Cancer, Leukemia and Cancer Vaccines
11. Reportlinker Adds Triple Analysis: Leukemia, Lymphoma and Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... Oramed Pharmaceuticals Inc. (NASDAQ: ... on the development of oral drug delivery systems, announced today ... conference, presented by Joseph Gunnar & Co. LLC, ... York . Nadav Kidron , CEO of Oramed, ... Presentation Details:   PIONEERS 2016, presented by ...
(Date:4/27/2016)... Mass., April 27, 2016  Hologic, Inc. (Nasdaq: ... financial results for the fiscal second quarter ended ... (EPS) of $0.24 increased 41.2%, and non-GAAP diluted ... million increased 5.8% on a reported basis, and ... "We posted another good quarter, highlighted by ...
(Date:4/27/2016)... 27, 2016 Transparency Market Research ... Market - Global Industry Analysis, Size, Share, Growth, Trends, ... the global skincare devices market was valued at US$ ... at a CAGR of 10.1% from 2015 to 2023 ... Browse the full Skincare Devices Market (Treatment Device - LED ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... 2016 , ... In an article published April 16th on the ... and lip injections, which she underwent in order to feel more at home at ... Festival. The article explains that Ms. Mirmelli’s situation is not unique; many plastic surgeons ...
(Date:4/29/2016)... Newport Beach, Calif. (PRWEB) , ... April 29, 2016 , ... ... affect us. An effective way to confront and deal with these stressors is to ... taste bad to be good for you. Risa Groux, a certified Holistic Nutritionist and ...
(Date:4/29/2016)... ... April 29, 2016 , ... The White House announced ... loans, more information about their loan terms and accounts, and more protections for ... including federal and private loans, has reached $1.3 trillion, with 43 million Americans ...
(Date:4/29/2016)... ... April 29, 2016 , ... Spine Team Texas, a comprehensive spine physician ... one of their physicians has been invited to be a featured speaker at the ... Review conference on April 30, 2016. , Dr. R. Scott McPherson, a physical ...
(Date:4/29/2016)... ON (PRWEB) , ... April 29, 2016 , ... ... and the Canadian Celiac Association (CCA), is pleased to announce the launch of ... gluten-free products, nutritional articles, recipes, and more. The purpose of the GFCP ...
Breaking Medicine News(10 mins):